Big Pharma helps tackle neglected diseases
London - The world’s major pharmaceutical companies joined forces with governments and leading global health organisations on Monday to donate drugs and scientific know-how to help control or wipe out 10 neglected tropical diseases by 2020.
Drugmakers have been criticised in the past for not doing enough to fight diseases of the poor as they concentrate instead on conditions more prevalent in rich nations, such as high cholesterol.
But in the largest coordinated effort yet to fight diseases such as Guinea worm disease, leprosy and sleeping sickness, the group promised to give away 14 billion doses of medicines by the end of this decade.
They will also share expertise and drug discovery work to invent new medicines for neglected tropical diseases (NTDs) that as yet have no treatments.
The AIDS pandemic forced the drug companies in the past decade to pay more attention to the developing world, and a new focus on the economic potential of emerging markets has given drug companies an incentive to promote their brands in developing countries.
In a project expected to affect the lives of a billion people worldwide, the drugmakers pledged more than $785m to support NTD research and development (R&D) and strengthen drug distribution and treatment programmes.
World Health Organisation (WHO) director general Margaret Chan, who announced the deal in London, said it “changes the face” of NTDs - illnesses that needlessly disable, blind and kill millions of the world’s poorest people.
“These ancient diseases are now being brought to their knees with stunning speed,” she told an audience at the Royal College of Physicians. “With the boost to this momentum being made today, I am confident almost all of these diseases can be eliminated or controlled by the end of this decade.”
NTDs disproportionally affect people in the poorest countries of the world. Experts estimate more than a billion people are affected by them, including more than 500 million children.
The WHO’s first global report on neglected tropical diseases in 2010 said that while they cost billions of dollars in lost productivity, they are often ignored because they affect mainly poor people and do not offer a profitable market for drugmakers.
NTDs include illnesses such as sleeping sickness, which is transmitted through tsetse fly bites and threatens millions of people in Africa, and Chagas disease, a debilitating condition caused by a parasite transmitted in infected faeces of blood-sucking bugs. An estimated 10 million people are infected with Chagas, mostly in Latin America where the disease is endemic.
Speaking for chief executives of the drug firms involved in the partnership, Andrew Witty, GlaxoSmithKline’s CEO described the impact of the diseases as “horrific” and said he hoped the scale of this new cooperation would beat them. “No one company or organisation can do it alone,” he said.
Adding the new pledges to existing individual commitments, 13 drug companies including Pfizer, Merck, Johnson & Johnson, Sanofi GlaxoSmithKline, Novartis and others will donate an average of 1.4 billion treatments a year to people suffering from NTDs.
The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) said new R&D collaborations and deals with drugmakers and the Drugs for Neglected Diseases initiative (DNDi) would also give “unprecedented” access to libraries of chemical compounds that may lead to new treatments.
Extra funding for the project came from Britain, the United States and United Arab Emirates, the Gates Foundation and the Children’s Investment Fund Foundation. The World Bank agreed to extend financing to help African countries build health systems better able to integrate NTD elimination and control.
Multi-billionaire philanthropist Bill Gates, whose foundation announced a five-year, $363m commitment to support NTD product and operational research, said the collaboration would help millions of people build self-sufficiency and overcome the need for aid and serve as a model for tackling future global development challenges.